CRISPR Therapeutics (NasdaqGM:CRSP) recently announced the departure of Chief Operating Officer Julianne Bruno, reflecting a notable leadership change that could influence its operational direction.

With the citrus industry at a crossroads, growers are looking for any solution to cope with the deadly citrus greening ...

A Peninsula biotech company raised $68 million from investors — including a venture philanthropy fund started by Lululemon ...

In a medical first, a research team in China has successfully stitched a CRISPR gene-edited pig liver into a brain-dead ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

Now, Johns Hopkins Medicine scientists say they have shed new light on how bacteria protect themselves from certain phage ...

Decades ago, Amber Salzman remembers feeling like there was nothing she could do to help her cousin-in-law with a progressive ...

Crispr Therapeutics said Chief Operating Officer Julianne Bruno would depart the company to pursue other opportunities, effective April 11. Bruno joined the gene-editing company in 2019 and stepped ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...